Skip to content
Menu

Evidence review

Compounded Tirzepatide Cost: The Real Monthly

What compounded tirzepatide costs per month across 508 tracked providers, what the step across from semaglutide really adds, and where the 503A rules stand now.

By The Desk, Provider Intelligence Desk
On this page

The Desk's #1 pick

CoreAge Rx

A

The Desk's top dispatch: one price at every dose, both molecules, all 50 states — but the $99 and $149 figures are 12-month plans paid up front, not a monthly bill.

Check availability
Semaglutide
$99/mo only as a 12-month plan paid in full ($1,188 in one charge); the lander says "starting at, based on a 12-month plan paid in full"; no month-to-month price is published; same price at every dose; compounded injectable
Tirzepatide
$149/mo only as a 12-month plan paid in full ($1,788 in one charge); no month-to-month price is published; same price at every dose; compounded injectable
Coverage
All 50 states
Access
Compounded

Advertising disclosure · we may earn a commission at no extra cost to you. It never changes what we write about a product — an unflattering finding on a paying provider stays in.

Also here

Oak

C

Nationwide, package-based and quick to approve, at $200/mo for compounded semaglutide and $250 for tirzepatide — one flat rate at every dose. The catch is not secrecy but inconsistency: its advertising carries nine different "starting" prices and none of them is what it charges.

Check Oak availability

Tirzepatide is the more expensive molecule, and buyers usually arrive at it after pricing semaglutide, which makes the interesting number not the price but the difference. This page reports both from the prices as they are actually filed, with the rows that do not qualify counted rather than hidden. Prices checked 2026-08-29.

What a month costs across the field

Of the 508 providers tracked here, 157 file a tirzepatide price that is dated, unconditional and genuinely monthly. Those run from $126 to $599, with a median of $269. A quarter sit at or below $199 and a quarter at or above $330.

By band, none of the 157 come in under $100, 43 fall between $100 and $199, 69 between $200 and $299, and 45 sit at $300 or more. That right-hand weight is the whole difference from the semaglutide picture, where the same exercise puts 95 rows in the $100 to $199 band. The verification dates on the qualifying rows run from 2026-06-06 to 2026-08-29.

Excluded, with reasons: 152 cells carry a condition that makes the figure something other than a standing monthly rate, 12 are brand-name prices, 13 carry no verification date, and 174 publish no tirzepatide price at all. The sorted ladder is at cheapest tirzepatide, and the compounded-only field is at best compounded tirzepatide.

What the step across from semaglutide costs

A provider that sells both molecules prices the upgrade, and that is a cleaner comparison than any cross-provider one because it holds the clinic, the pharmacy and the billing term constant.

Comparing only pairs where both cells carry the same condition, 229 providers here quote both molecules comparably. The median step across is $70 a month. A quarter of those pairs charge $46 or less for it and a quarter charge $100 or more, and the full range runs from minus $180 to plus $350. Twenty-six pairs price tirzepatide at or below their own semaglutide line, which is worth knowing if you assumed the premium was universal. The ranked view of who charges what for the step is on the tirzepatide ranking.

Why the spread runs $126 to $599

The same four levers move a tirzepatide quote as a semaglutide one, and they move it harder because the base number is bigger.

Dose is the first: 105 of the 334 tirzepatide cells carrying a dollar figure are floors quoted at the starting strength, and tirzepatide titrates across six approved strengths, so the gap between the advertised month and the maintenance month is wide. Billing term is the second: 21 cells price a prepay plan, and a monthly figure that only exists because a quarterly charge was divided is not a monthly price. The Pallas Health review is the clearest case on this site of an advertised monthly average that is really one large charge split three ways.

What is bundled is the third lever. 6 cells are membership-gated, with a separate recurring fee beside the medication charge. Duration is the fourth: 9 cells are promotional rates and 3 are first-month rates. Only 174 of the 334 are a flat month-to-month figure at every dose. If you want a number you can plan around, that is the subset to shop in, and the Ondra Health review is an example of a listing that publishes its month-to-month rate and its quarterly rate side by side rather than picking the flattering one.

Where the law stands, as of August 2026

Compounded drugs are not FDA-approved; the agency does not verify their safety, effectiveness or quality before they are marketed2. That is true of every row above.

Tirzepatide's compounding lane narrowed first. The FDA declared the tirzepatide shortage resolved on December 19, 2024, and after a federal court declined to enjoin that decision in March 2025 the enforcement discretion for 503A pharmacies ended; the 503B window closed on March 19, 20251. The agency's current position is stated flatly on its own page: "Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list"1. On April 30, 2026 the FDA proposed to exclude both, plus liraglutide, from that bulks list outright, "finding no clinical need for outsourcing facilities to compound these drugs from bulk substances"3. Comments closed July 30, 20264, and a Federal Register check on 2026-08-29 found no final determination.

Practically, that means a compounded tirzepatide vial today should come from a named, state-licensed 503A pharmacy compounding against your prescription. A seller claiming an outsourcing-facility source for tirzepatide should be asked how that squares with the FDA's own page. The longer version is in is compounded GLP-1 legit and safe.

The brand comparison, and what you give up

Lilly's own savings page prices the approved product by strength: "Regular price for a 1-month supply of Zepbound single-patient-use KwikPen is $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, $699 for 10 mg, $699 for 12.5 mg, and $699 for 15 mg"5. Against that ladder the $269 median above undercuts every strength above the lowest one, and it undercuts them by more as you titrate.

What the brand carries that no compounded vial does is its own evidence. In SURMOUNT-1, tirzepatide produced weight reductions up to roughly 21% at the 15 mg dose over 72 weeks6. That trial tested the manufacturer's product, not a compounded copy of it.

The semaglutide version of this breakdown is at compounded semaglutide cost, the brand and Medicare routes are in GLP-1 cost without insurance, and if the molecule choice itself is still open, start with semaglutide vs tirzepatide. Sources are indexed in our research library.

Frequently asked questions

How much does compounded tirzepatide cost per month?

Across the 508 providers tracked here on 2026-08-29, 157 filed a dated, unconditional month-to-month tirzepatide price. They ran from $126 to $599 with a median of $269; a quarter were at or below $199 and a quarter at or above $330.

How much more is tirzepatide than semaglutide at the same clinic?

Comparing only pairs where both prices carry the same condition, 229 providers here quote both molecules comparably. The median step across is $70 a month, the middle half falls between $46 and $100, and 26 of those pairs price tirzepatide at or below their own semaglutide line.

Is compounded tirzepatide still legal?

Through a state-licensed 503A pharmacy compounding against an individual prescription, yes. The 503B outsourcing-facility route closed in March 2025 once the shortage ended, and in April 2026 the FDA proposed removing tirzepatide from the 503B bulks list altogether. No final determination had been published as of 2026-08-29.

Why do compounded tirzepatide prices climb so much with dose?

Because 105 of the 334 tirzepatide price cells here are quoted at a starting strength, and tirzepatide titrates across six approved strengths. The advertised figure often describes the first month rather than the maintenance month, so ask which dose a quote covers before comparing it to anything.

References

  1. U.S. Food and Drug Administration (2026). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA.gov. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  2. U.S. Food and Drug Administration (2025). Compounding and the FDA: Questions and Answers. FDA.gov. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  3. U.S. Food and Drug Administration (2026). FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. FDA.gov press announcement. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  4. U.S. Food and Drug Administration (2026). List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period (91 FR 38719). Federal Register. https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
  5. Eli Lilly and Company (2026). Savings & Insurance Options — Zepbound (tirzepatide). Zepbound.lilly.com. https://zepbound.lilly.com/coverage-savings
  6. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/35658024/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Continue reading